<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01574703</url>
  </required_header>
  <id_info>
    <org_study_id>A3051148</org_study_id>
    <secondary_id>2011-005513-37</secondary_id>
    <secondary_id>CATS</secondary_id>
    <nct_id>NCT01574703</nct_id>
  </id_info>
  <brief_title>Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.</brief_title>
  <acronym>CATS</acronym>
  <official_title>A Phase 4, Non-treatment Follow-up For Cardiac Assessments Following Use Of Smoking Cessation Treatments In Subjects With And Without A History Of Psychiatric Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-treatment extension to study A3051123, aimed at collecting data on cardiovascular safety
      for all participants in the A3051123 trial for an additional 28 weeks, allowing for a total
      of 52 weeks of cardiovascular safety data collection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an extension protocol for study A3051123. No treatment is provided during this
      study. This study is to monitor for cardiovascular events 28 weeks after completion of
      A3051123. This study is an extension protocol for study A3051123. No treatment is provided
      during this study. This study is to monitor for cardiovascular events 28 weeks after
      completion of A3051123.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Occurrence of Major Adverse Cardiovascular Event (MACE) During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.</measure>
    <time_frame>Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks).</time_frame>
    <description>This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug). The measure type mentioned in the outcome data table is Hazard Ratio relative to Placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to MACE up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.</measure>
    <time_frame>Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks) plus 30 days.</time_frame>
    <description>This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug) plus 30 days follow-up. The measure type mentioned in the outcome data table is Hazard Ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to MACE Until the End of Study NCT01574703.</measure>
    <time_frame>Baseline until end of study (end of study is defined as last visit in study NCT01574703 [up to Week 52], or in study NCT01456936 [up to 24 Weeks] for those participants not enrolled into study NCT01574703).</time_frame>
    <description>This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated until end of study. The measure type mentioned in the outcome data table is Hazard Ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of MACE Assessed During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.</measure>
    <time_frame>Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks).</time_frame>
    <description>This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of MACE + Assessed During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.</measure>
    <time_frame>Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks).</time_frame>
    <description>This is an adjudicated endpoint. MACE + is defined as any MACE or a new onset or worsening peripheral vascular disease (PVD) requiring intervention, a need for coronary revascularization, or hospitalization for unstable angina.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of MACE Assessed up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.</measure>
    <time_frame>Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks) plus 30 days follow-up.</time_frame>
    <description>This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug) plus 30 days follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of MACE+ Assessed up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.</measure>
    <time_frame>Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks) plus 30 days follow-up.</time_frame>
    <description>This is an adjudicated endpoint. MACE + is defined as any MACE or a new onset or worsening PVD requiring intervention, a need for coronary revascularization, or hospitalization for unstable angina.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of MACE Assessed Until End of Study NCT01574703.</measure>
    <time_frame>Baseline until end of study (end of study is defined as last visit in study NCT01574703 [up to Week 52], or in study NCT01456936 [up to 24 Weeks] for those participants not enrolled into study NCT01574703).</time_frame>
    <description>This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated until end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of MACE+ Assessed Until End of Study NCT01574703.</measure>
    <time_frame>Baseline until end of study (end of study is defined as last visit in study NCT01574703 [up to Week 52], or in study NCT01456936 [up to 24 Weeks] for those participants not enrolled into study NCT01574703).</time_frame>
    <description>This is an adjudicated endpoint. MACE+ is defined as any MACE or a new onset or worsening PVD requiring intervention, a need for coronary revascularization, or hospitalization for unstable angina.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">4595</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>varenicline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine Replacement Therapy Patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>All dosing to have taken place per study A3051123</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>varenicline tartrate</intervention_name>
    <description>All dosing to have taken place per study A3051123</description>
    <arm_group_label>varenicline</arm_group_label>
    <other_name>Chantix; Champix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupropion hydrochloride</intervention_name>
    <description>All dosing to have taken place per study A3051123</description>
    <arm_group_label>bupropion</arm_group_label>
    <other_name>Zyban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine Replacement Therapy Patch</intervention_name>
    <description>All dosing to have taken place per study A3051123</description>
    <arm_group_label>Nicotine Replacement Therapy Patch</arm_group_label>
    <other_name>NRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will be eligible if they were randomized to study A3051123.

        Exclusion Criteria:

          -  Participation in study A3051123 ceased (ie, withdrew consent, lost to follow-up, etc)
             prior to final visit of study A3051123.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Coastal Clinical Research, Inc.</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy Clinical Research Center of Escondido</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Valley Research Center</name>
      <address>
        <city>Imperial</city>
        <state>California</state>
        <zip>92251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Clinical Trials</name>
      <address>
        <city>La Habra</city>
        <state>California</state>
        <zip>90631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Treatment and Research Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute (PRI)</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North County Clinical Research</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NRC Research Institute</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Neuroscience Research Medical Group, Inc.</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus Behavioral Health and Wellness Program</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Affiliated Research Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Psychiatric Care</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatric Research Center of Southwest Florida</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broward Research Group</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocala Psychiatric Associates</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions Inc.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33634</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Behavioral Research Center</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Atlanta</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baber Research Group Incorporated</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Davis Clinic, Incorporated</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Network of IN, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goldpoint Clinical Research, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vince &amp; Associates Clinical Research, Inc.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vince &amp; Associates Clinical Research, Inc.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vince and Associates Clinical Research, Inc.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Research Associates, Incorporated</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Research Group</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Sexual Health</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Research Associates</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milford Emergency Associates, Incorporated</name>
      <address>
        <city>Milford</city>
        <state>Massachusetts</state>
        <zip>01757</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota - TC</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precise Research Centers</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Pharmaceutical Research, PC</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Health Research</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRI Worldwide, LLC</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Medicinal Institutes, LLC; Princeton Medical Institute</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPRI Clinical Trails LLC</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Research, Incorporated</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Raleigh, LLC</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Internal Medicine Consultants, Inc</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern PA Medical Institute</name>
      <address>
        <city>Broomall</city>
        <state>Pennsylvania</state>
        <zip>19008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belmont Center for Comprehensive Treatment</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lincoln Research, LLC</name>
      <address>
        <city>Lincoln</city>
        <state>Rhode Island</state>
        <zip>02865</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volunteer Research Group</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions,Inc</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates, Inc.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James G. Kyser, MD</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Future Search Clinical Trials</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InSite Clinical Research</name>
      <address>
        <city>DeSoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-1439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates of Tidewater, Inc</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Clinica WM</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>C1440BRR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Dra. De Salvo</name>
      <address>
        <city>Buenos Aires</city>
        <state>Capital Federal</state>
        <zip>C1426ABP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Alfred Psychiatry Research Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Lucas da PUCRS - Uniao Brasileira de Educacao e Assistencia</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital e Maternidade Celso Pierro - Pontifícia Universidade Católica de Campinas - Campus II</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <zip>13059-740</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jaqueline Scholz Issa e Mario Issa de cardiologia Ltda</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05017-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mental Health Center &quot;Prof. Dr. Ivan Temkov-Bourgas&quot; Ltd.</name>
      <address>
        <city>Bourgas</city>
        <zip>8000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Dr. Hristo Stambolski&quot; Ltd.</name>
      <address>
        <city>Kazanlak</city>
        <zip>6100</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NPH &quot;Sv. Ivan Rilski&quot;</name>
      <address>
        <city>Novi Iskar</city>
        <zip>1282</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;Dr. Georgi Stranski&quot; Ltd.</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;Sveti Georgi&quot; Ltd.</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHATPPD - Ruse Ltd.</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mental Health Center - Ruse Ltd.</name>
      <address>
        <city>Ruse</city>
        <zip>7004</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHATNP &quot;Sveti Naum&quot; Ltd.</name>
      <address>
        <city>Sofia</city>
        <zip>1113</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHATNP Sveti Naum SJsc.</name>
      <address>
        <city>Sofia</city>
        <zip>1113</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHATPD - Troyan Ltd.</name>
      <address>
        <city>Troyan</city>
        <zip>5600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Medical Research Group</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8M 1K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Associates</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 4N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canadian Phase Onward Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3J 2C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health (CAMH)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 2S1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diex Research Sherbrooke Inc.</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional de Talca, Unidad de Enfermedades Respiratorias</name>
      <address>
        <city>Talca</city>
        <state>Maule</state>
        <zip>3460001</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Respiratorio Integral (CENRESIN Ltda.)</name>
      <address>
        <city>Quillota</city>
        <state>Valparaiso, V Region</state>
        <zip>2260877</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR A/S</name>
      <address>
        <city>Ballerup</city>
        <zip>2750</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR A/S</name>
      <address>
        <city>Vejle</city>
        <zip>DK-7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mehiläinen Leppävaara</name>
      <address>
        <city>Espoo</city>
        <zip>02600</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Savon Psykiatripalvelu Oy</name>
      <address>
        <city>Kuopio</city>
        <zip>70110</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mehiläinen Nummela</name>
      <address>
        <city>Nummela</city>
        <zip>03100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oulu Mentalcare Oy</name>
      <address>
        <city>Oulu</city>
        <zip>90100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Porin Lääkäritalo Oy</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PEL, Psykiatrian ErikoisLääkärit</name>
      <address>
        <city>Turku</city>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-wuerttemberg</state>
        <zip>79104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwig Maximilians-Universitaet Muenchen</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Berlin-Mitte GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>emovis GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10629</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Hamburg GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20253</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZSL - Zentrum fuer Medizinische Studien Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Tuebingen, Klinik fuer Psychiatrie und Psychotherapie</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorios de Medicina Especializada del Sector Privado</name>
      <address>
        <city>Mexico</city>
        <state>Mexico Df</state>
        <zip>06100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudios Clinicos y Especialidades Medicas S.C.</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64620</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeland Clinical Trials</name>
      <address>
        <city>Rotorua</city>
        <zip>3010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBI &quot;Federal Medical Research Center of Psychiatry and Addiction Medicine&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>107076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow State Public Healthcare Institution Mental Clinical Hospital #1 n.a. N.A. Alexeeva</name>
      <address>
        <city>Moscow</city>
        <zip>117152</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Mental Hospital #12 of Moscow Healthcare Department</name>
      <address>
        <city>Moscow</city>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Psychiatric Hospital #1 of Nizhni Novgorod</name>
      <address>
        <city>Nizhni Novgorod</city>
        <zip>603155</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBI &quot;Saint-Petersburg Scientific Research Psychoneurological Institute n.a. V.M. Bekhterev&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>192019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Healthcare Institution, St. Nikolay Chudotvorets Mental Hospital</name>
      <address>
        <city>St. Petersburg</city>
        <zip>190121</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution of St.Petersburg &quot;Psychoneurological Dispensary #2</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatricka ambulancia, Mentum, s.r.o.</name>
      <address>
        <city>Bratislava</city>
        <zip>82007</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nestatna psychiatricka ambulancia, MUDr. Livia Vavrusova, PhD</name>
      <address>
        <city>Bratislava</city>
        <zip>851 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatricka ambulancia MUDr. Nada Kuriackova, s.r.o.</name>
      <address>
        <city>Levice</city>
        <zip>93401</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatricka ambulancia, PsychoLine s.r.o.</name>
      <address>
        <city>Rimavska Sobota</city>
        <zip>979 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnica s poliklinikou sv. Barbory Roznava a.s.</name>
      <address>
        <city>Roznava</city>
        <zip>04801</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flexivest Fourteen Research Center</name>
      <address>
        <city>Bellville</city>
        <state>Cape Town</state>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Worthwhile Clinical Trials</name>
      <address>
        <city>Benoni, Johannesburg</city>
        <state>Gauteng</state>
        <zip>1500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soweto Clinical Trials Centre</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1818</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midrand Medical Centre</name>
      <address>
        <city>Midrand</city>
        <state>Gauteng</state>
        <zip>1685</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I Engelbrecht Research Pty. Ltd</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0157</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vista Clinic</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0157</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Durban</city>
        <state>Kwa-zulu Natal, South Africa</state>
        <zip>4019</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Randles Road Medical Centre</name>
      <address>
        <city>Durban</city>
        <state>Kwazulu Natal</state>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr John O'Brien Incorporated</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>8001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de La Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitari Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcantara</name>
      <address>
        <city>Caceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad Especializada En Tabaquismo de La Comunidad de Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Salud Torrero-La Paz.</name>
      <address>
        <city>Zaragoza</city>
        <zip>50007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3051148&amp;StudyName=Study%20To%20Evaluate%20Cardiac%20Assessments%20Following%20Different%20Treatments%20Of%20Smoking%20Cessation%20Medications%20In%20Subjects%20With%20And%20without%20Psychiatr</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2012</study_first_submitted>
  <study_first_submitted_qc>April 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2012</study_first_posted>
  <results_first_submitted>July 7, 2016</results_first_submitted>
  <results_first_submitted_qc>October 31, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 29, 2016</results_first_posted>
  <last_update_submitted>October 31, 2016</last_update_submitted>
  <last_update_submitted_qc>October 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>smoking cessation</keyword>
  <keyword>psychiatric disease</keyword>
  <keyword>cardiovascular events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Problem Behavior</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Varenicline</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Of the 6293 participants who completed the parent study NCT01456936 as per protocol, a total of 4595 participants enrolled into this study NCT01574703 from 132 centers in 16 countries.</recruitment_details>
      <pre_assignment_details>This is a non-treatment extension study of parent study NCT01456936. No study drug was provided in this extension phase. However, cardiovascular events that occurred during parent study NCT01456936 when participants received varenicline(N=2016), bupropion(N=2006),NRT(N=2022), or placebo(N=2014) in a triple-dummy design were analyzed in this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Varenicline</title>
          <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received varenicline in a triple-dummy design were analyzed as part of this study.</description>
        </group>
        <group group_id="P2">
          <title>Bupropion</title>
          <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received bupropion in a triple-dummy design were analyzed as part of this study.</description>
        </group>
        <group group_id="P3">
          <title>Nicotine Replacement Therapy (NRT) Patch</title>
          <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received NRT patch in a triple-dummy design were analyzed as part of this study.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received placebo in a triple-dummy design were analyzed as part of this study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1192"/>
                <participants group_id="P2" count="1166"/>
                <participants group_id="P3" count="1116"/>
                <participants group_id="P4" count="1121"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1067"/>
                <participants group_id="P2" count="1054"/>
                <participants group_id="P3" count="1011"/>
                <participants group_id="P4" count="1007"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="112"/>
                <participants group_id="P3" count="105"/>
                <participants group_id="P4" count="114"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unspecified Reason</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="61"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met Withdrawal Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="46"/>
                <participants group_id="P4" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The term Baseline visit refers to the Baseline (Week 0) visit of the parent study NCT01456936. The safety population included all participants who received at least one dose of study drug in NCT01456936 parent study. The below Baseline characteristics (age, gender) are presented for all participants who entered study NCT01574703.</population>
      <group_list>
        <group group_id="B1">
          <title>Varenicline</title>
          <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received varenicline in a triple-dummy design were analyzed as part of this study.</description>
        </group>
        <group group_id="B2">
          <title>Bupropion</title>
          <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received bupropion in a triple-dummy design were analyzed as part of this study.</description>
        </group>
        <group group_id="B3">
          <title>NRT Patch</title>
          <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received NRT patch in a triple-dummy design were analyzed as part of this study.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received placebo in a triple-dummy design were analyzed as part of this study.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1192"/>
            <count group_id="B2" value="1166"/>
            <count group_id="B3" value="1116"/>
            <count group_id="B4" value="1121"/>
            <count group_id="B5" value="4595"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.1" spread="12.2"/>
                    <measurement group_id="B2" value="47.7" spread="12.5"/>
                    <measurement group_id="B3" value="48.3" spread="11.9"/>
                    <measurement group_id="B4" value="47.5" spread="12.2"/>
                    <measurement group_id="B5" value="47.9" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="659"/>
                    <measurement group_id="B2" value="648"/>
                    <measurement group_id="B3" value="623"/>
                    <measurement group_id="B4" value="621"/>
                    <measurement group_id="B5" value="2551"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="533"/>
                    <measurement group_id="B2" value="518"/>
                    <measurement group_id="B3" value="493"/>
                    <measurement group_id="B4" value="500"/>
                    <measurement group_id="B5" value="2044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Occurrence of Major Adverse Cardiovascular Event (MACE) During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.</title>
        <description>This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug). The measure type mentioned in the outcome data table is Hazard Ratio relative to Placebo.</description>
        <time_frame>Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks).</time_frame>
        <population>The safety analysis set is defined as all participants that received at least one partial dose of study drug during the parent study NCT01456936.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received varenicline in a triple-dummy design were analyzed as part of this study.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received bupropion in a triple-dummy design were analyzed as part of this study.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received NRT patch in a triple-dummy design were analyzed as part of this study.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received placebo in a triple-dummy design were analyzed as part of this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Occurrence of Major Adverse Cardiovascular Event (MACE) During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.</title>
          <description>This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug). The measure type mentioned in the outcome data table is Hazard Ratio relative to Placebo.</description>
          <population>The safety analysis set is defined as all participants that received at least one partial dose of study drug during the parent study NCT01456936.</population>
          <units>Unitless</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2016"/>
                <count group_id="O2" value="2006"/>
                <count group_id="O3" value="2022"/>
                <count group_id="O4" value="2014"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" lower_limit="0.05" upper_limit="1.68"/>
                    <measurement group_id="O2" value="0.50" lower_limit="0.10" upper_limit="2.50"/>
                    <measurement group_id="O3" value="0.29" lower_limit="0.05" upper_limit="1.70"/>
                    <measurement group_id="O4" value="NA">Hazard ratio relative to Placebo.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for overall treatment comparison.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.37</p_value>
            <p_value_desc>P-value for the treatment effect from the Log-Rank test stratified by Cohort.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to MACE up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.</title>
        <description>This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug) plus 30 days follow-up. The measure type mentioned in the outcome data table is Hazard Ratio.</description>
        <time_frame>Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks) plus 30 days.</time_frame>
        <population>The safety analysis set is defined as all participants that received at least one partial dose of study drug during the parent study NCT01456936.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received varenicline in a triple-dummy design were analyzed as part of this study.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received bupropion in a triple-dummy design were analyzed as part of this study.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received NRT patch in a triple-dummy design were analyzed as part of this study.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received placebo in a triple-dummy design were analyzed as part of this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to MACE up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.</title>
          <description>This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug) plus 30 days follow-up. The measure type mentioned in the outcome data table is Hazard Ratio.</description>
          <population>The safety analysis set is defined as all participants that received at least one partial dose of study drug during the parent study NCT01456936.</population>
          <units>Unitless</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2016"/>
                <count group_id="O2" value="2006"/>
                <count group_id="O3" value="2022"/>
                <count group_id="O4" value="2014"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" lower_limit="0.05" upper_limit="1.70"/>
                    <measurement group_id="O2" value="0.51" lower_limit="0.10" upper_limit="2.51"/>
                    <measurement group_id="O3" value="0.50" lower_limit="0.10" upper_limit="2.48"/>
                    <measurement group_id="O4" value="NA">Hazard ratio relative to Placebo.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for overall treatment comparison.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.53</p_value>
            <p_value_desc>P-value for the treatment effect from the Log-Rank test stratified by Cohort.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to MACE Until the End of Study NCT01574703.</title>
        <description>This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated until end of study. The measure type mentioned in the outcome data table is Hazard Ratio.</description>
        <time_frame>Baseline until end of study (end of study is defined as last visit in study NCT01574703 [up to Week 52], or in study NCT01456936 [up to 24 Weeks] for those participants not enrolled into study NCT01574703).</time_frame>
        <population>The safety analysis set is defined as all participants that received at least one partial dose of study drug during the parent study NCT01456936.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received varenicline in a triple-dummy design were analyzed as part of this study.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received bupropion in a triple-dummy design were analyzed as part of this study.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received NRT patch in a triple-dummy design were analyzed as part of this study.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received placebo in a triple-dummy design were analyzed as part of this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to MACE Until the End of Study NCT01574703.</title>
          <description>This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated until end of study. The measure type mentioned in the outcome data table is Hazard Ratio.</description>
          <population>The safety analysis set is defined as all participants that received at least one partial dose of study drug during the parent study NCT01456936.</population>
          <units>Unitless</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2016"/>
                <count group_id="O2" value="2006"/>
                <count group_id="O3" value="2022"/>
                <count group_id="O4" value="2014"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" lower_limit="0.12" upper_limit="1.27"/>
                    <measurement group_id="O2" value="1.09" lower_limit="0.42" upper_limit="2.83"/>
                    <measurement group_id="O3" value="0.75" lower_limit="0.26" upper_limit="2.13"/>
                    <measurement group_id="O4" value="NA">Hazard ratio relative to Placebo.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for overall treatment comparison.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.34</p_value>
            <p_value_desc>P-value for the treatment effect from the Log-Rank test stratified by Cohort.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of MACE Assessed During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.</title>
        <description>This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug).</description>
        <time_frame>Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks).</time_frame>
        <population>The safety analysis set is defined as all participants that received at least one partial dose of study drug during the parent study NCT01456936.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received varenicline in a triple-dummy design were analyzed as part of this study.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received bupropion in a triple-dummy design were analyzed as part of this study.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received NRT patch in a triple-dummy design were analyzed as part of this study.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received placebo in a triple-dummy design were analyzed as part of this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of MACE Assessed During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.</title>
          <description>This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug).</description>
          <population>The safety analysis set is defined as all participants that received at least one partial dose of study drug during the parent study NCT01456936.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2016"/>
                <count group_id="O2" value="2006"/>
                <count group_id="O3" value="2022"/>
                <count group_id="O4" value="2014"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05"/>
                    <measurement group_id="O2" value="0.10"/>
                    <measurement group_id="O3" value="0.05"/>
                    <measurement group_id="O4" value="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Varenicline and Bupropion.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8375</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.22</ci_lower_limit>
            <ci_upper_limit>4.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Varenicline and NRT patch.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9780</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.20</ci_lower_limit>
            <ci_upper_limit>5.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Varenicline and Placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6142</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.54</ci_lower_limit>
            <ci_upper_limit>3.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Bupropion and NRT patch.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8602</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.28</ci_lower_limit>
            <ci_upper_limit>5.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Bupropion and Placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7217</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.15</ci_lower_limit>
            <ci_upper_limit>2.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between NRT patch and Placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6322</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.41</ci_lower_limit>
            <ci_upper_limit>3.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of MACE + Assessed During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.</title>
        <description>This is an adjudicated endpoint. MACE + is defined as any MACE or a new onset or worsening peripheral vascular disease (PVD) requiring intervention, a need for coronary revascularization, or hospitalization for unstable angina.</description>
        <time_frame>Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks).</time_frame>
        <population>The safety analysis set is defined as all participants that received at least one partial dose of study drug during the parent study NCT01456936.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received varenicline in a triple-dummy design were analyzed as part of this study.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received bupropion in a triple-dummy design were analyzed as part of this study.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received NRT patch in a triple-dummy design were analyzed as part of this study.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received placebo in a triple-dummy design were analyzed as part of this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of MACE + Assessed During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.</title>
          <description>This is an adjudicated endpoint. MACE + is defined as any MACE or a new onset or worsening peripheral vascular disease (PVD) requiring intervention, a need for coronary revascularization, or hospitalization for unstable angina.</description>
          <population>The safety analysis set is defined as all participants that received at least one partial dose of study drug during the parent study NCT01456936.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2016"/>
                <count group_id="O2" value="2006"/>
                <count group_id="O3" value="2022"/>
                <count group_id="O4" value="2014"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25"/>
                    <measurement group_id="O2" value="0.20"/>
                    <measurement group_id="O3" value="0.10"/>
                    <measurement group_id="O4" value="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Varenicline and Bupropion.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9687</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.48</ci_lower_limit>
            <ci_upper_limit>3.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Varenicline and NRT patch.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7905</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.58</ci_lower_limit>
            <ci_upper_limit>4.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Varenicline and Placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8962</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.36</ci_lower_limit>
            <ci_upper_limit>2.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Bupropion and NRT patch.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7767</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.72</ci_lower_limit>
            <ci_upper_limit>4.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Bupropion and Placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9260</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.13</ci_lower_limit>
            <ci_upper_limit>2.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between NRT patch and Placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7113</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.85</ci_lower_limit>
            <ci_upper_limit>3.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of MACE Assessed up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.</title>
        <description>This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug) plus 30 days follow-up.</description>
        <time_frame>Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks) plus 30 days follow-up.</time_frame>
        <population>The safety analysis set is defined as all participants that received at least one partial dose of study drug during the parent study NCT01456936.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received varenicline in a triple-dummy design were analyzed as part of this study.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received bupropion in a triple-dummy design were analyzed as part of this study.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received NRT patch in a triple-dummy design were analyzed as part of this study.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received placebo in a triple-dummy design were analyzed as part of this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of MACE Assessed up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.</title>
          <description>This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug) plus 30 days follow-up.</description>
          <population>The safety analysis set is defined as all participants that received at least one partial dose of study drug during the parent study NCT01456936.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2016"/>
                <count group_id="O2" value="2006"/>
                <count group_id="O3" value="2022"/>
                <count group_id="O4" value="2014"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05"/>
                    <measurement group_id="O2" value="0.10"/>
                    <measurement group_id="O3" value="0.10"/>
                    <measurement group_id="O4" value="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Varenicline and Bupropion.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8117</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.27</ci_lower_limit>
            <ci_upper_limit>4.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Varenicline and NRT patch.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7303</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.21</ci_lower_limit>
            <ci_upper_limit>3.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Varenicline and Placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5946</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.60</ci_lower_limit>
            <ci_upper_limit>3.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Bupropion and NRT patch.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9200</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.27</ci_lower_limit>
            <ci_upper_limit>3.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Bupropion and Placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7236</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.09</ci_lower_limit>
            <ci_upper_limit>2.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between NRT patch and Placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8201</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.01</ci_lower_limit>
            <ci_upper_limit>3.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of MACE+ Assessed up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.</title>
        <description>This is an adjudicated endpoint. MACE + is defined as any MACE or a new onset or worsening PVD requiring intervention, a need for coronary revascularization, or hospitalization for unstable angina.</description>
        <time_frame>Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks) plus 30 days follow-up.</time_frame>
        <population>The safety analysis set is defined as all participants that received at least one partial dose of study drug during the parent study NCT01456936.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received varenicline in a triple-dummy design were analyzed as part of this study.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received bupropion in a triple-dummy design were analyzed as part of this study.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received NRT patch in a triple-dummy design were analyzed as part of this study.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received placebo in a triple-dummy design were analyzed as part of this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of MACE+ Assessed up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.</title>
          <description>This is an adjudicated endpoint. MACE + is defined as any MACE or a new onset or worsening PVD requiring intervention, a need for coronary revascularization, or hospitalization for unstable angina.</description>
          <population>The safety analysis set is defined as all participants that received at least one partial dose of study drug during the parent study NCT01456936.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2016"/>
                <count group_id="O2" value="2006"/>
                <count group_id="O3" value="2022"/>
                <count group_id="O4" value="2014"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25"/>
                    <measurement group_id="O2" value="0.20"/>
                    <measurement group_id="O3" value="0.15"/>
                    <measurement group_id="O4" value="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Varenicline and Bupropion.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8932</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.22</ci_lower_limit>
            <ci_upper_limit>2.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Varenicline and NRT patch.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8747</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.09</ci_lower_limit>
            <ci_upper_limit>2.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Varenicline and Placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6710</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.35</ci_lower_limit>
            <ci_upper_limit>2.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Bupropion and NRT patch.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9886</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.32</ci_lower_limit>
            <ci_upper_limit>3.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Bupropion and Placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7631</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.92</ci_lower_limit>
            <ci_upper_limit>2.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between NRT patch and Placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8022</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.23</ci_lower_limit>
            <ci_upper_limit>2.50</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of MACE Assessed Until End of Study NCT01574703.</title>
        <description>This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated until end of study.</description>
        <time_frame>Baseline until end of study (end of study is defined as last visit in study NCT01574703 [up to Week 52], or in study NCT01456936 [up to 24 Weeks] for those participants not enrolled into study NCT01574703).</time_frame>
        <population>The safety analysis set is defined as all participants that received at least one partial dose of study drug during the parent study NCT01456936.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received varenicline in a triple-dummy design were analyzed as part of this study.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received bupropion in a triple-dummy design were analyzed as part of this study.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received NRT patch in a triple-dummy design were analyzed as part of this study.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received placebo in a triple-dummy design were analyzed as part of this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of MACE Assessed Until End of Study NCT01574703.</title>
          <description>This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated until end of study.</description>
          <population>The safety analysis set is defined as all participants that received at least one partial dose of study drug during the parent study NCT01456936.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2016"/>
                <count group_id="O2" value="2006"/>
                <count group_id="O3" value="2022"/>
                <count group_id="O4" value="2014"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15"/>
                    <measurement group_id="O2" value="0.45"/>
                    <measurement group_id="O3" value="0.30"/>
                    <measurement group_id="O4" value="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Varenicline and Bupropion.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6441</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.78</ci_lower_limit>
            <ci_upper_limit>2.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Varenicline and NRT patch.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7327</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.63</ci_lower_limit>
            <ci_upper_limit>3.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Varenicline and Placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6109</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.80</ci_lower_limit>
            <ci_upper_limit>2.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Bupropion and NRT patch.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8707</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.48</ci_lower_limit>
            <ci_upper_limit>2.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Bupropion and Placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9531</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.63</ci_lower_limit>
            <ci_upper_limit>2.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between NRT patch and Placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8262</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.99</ci_lower_limit>
            <ci_upper_limit>2.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of MACE+ Assessed Until End of Study NCT01574703.</title>
        <description>This is an adjudicated endpoint. MACE+ is defined as any MACE or a new onset or worsening PVD requiring intervention, a need for coronary revascularization, or hospitalization for unstable angina.</description>
        <time_frame>Baseline until end of study (end of study is defined as last visit in study NCT01574703 [up to Week 52], or in study NCT01456936 [up to 24 Weeks] for those participants not enrolled into study NCT01574703).</time_frame>
        <population>The safety analysis set is defined as all participants that received at least one partial dose of study drug during the parent study NCT01456936.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received varenicline in a triple-dummy design were analyzed as part of this study.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received bupropion in a triple-dummy design were analyzed as part of this study.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received NRT patch in a triple-dummy design were analyzed as part of this study.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received placebo in a triple-dummy design were analyzed as part of this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of MACE+ Assessed Until End of Study NCT01574703.</title>
          <description>This is an adjudicated endpoint. MACE+ is defined as any MACE or a new onset or worsening PVD requiring intervention, a need for coronary revascularization, or hospitalization for unstable angina.</description>
          <population>The safety analysis set is defined as all participants that received at least one partial dose of study drug during the parent study NCT01456936.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2016"/>
                <count group_id="O2" value="2006"/>
                <count group_id="O3" value="2022"/>
                <count group_id="O4" value="2014"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50"/>
                    <measurement group_id="O2" value="0.75"/>
                    <measurement group_id="O3" value="0.49"/>
                    <measurement group_id="O4" value="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Varenicline and Bupropion.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6105</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.84</ci_lower_limit>
            <ci_upper_limit>1.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Varenicline and NRT patch.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7895</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.65</ci_lower_limit>
            <ci_upper_limit>2.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Varenicline and Placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6804</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.75</ci_lower_limit>
            <ci_upper_limit>1.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Bupropion and NRT patch.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8127</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.95</ci_lower_limit>
            <ci_upper_limit>2.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between Bupropion and Placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9218</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.04</ci_lower_limit>
            <ci_upper_limit>2.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis between NRT patch and Placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8841</p_value>
            <p_value_desc>P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.32</ci_lower_limit>
            <ci_upper_limit>2.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from Week 24 visit of study NCT01456936 until the end of study (i.e. Week 52 or date of discontinuation, as applicable).</time_frame>
      <desc>Safety analysis set: Participants that received at least one dose of study drug during the parent study (i.e., NCT01456936). Four deaths (completed suicide, death, myocardial infarction and upper gastrointestinal haemorrhage) are listed as serious AEs below, included events that began 31 days after the last dose of study drug in study NCT01456936.</desc>
      <group_list>
        <group group_id="E1">
          <title>Varenicline</title>
          <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received varenicline in a triple-dummy design were analyzed as part of this study.</description>
        </group>
        <group group_id="E2">
          <title>Bupropion</title>
          <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received bupropion in a triple-dummy design were analyzed as part of this study.</description>
        </group>
        <group group_id="E3">
          <title>NRT Patch</title>
          <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received NRT patch in a triple-dummy design were analyzed as part of this study.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>This was the non-treatment extension study of parent study NCT01456936. No study drug was provided during this extension phase. However, Cardiovascular events that occurred during parent study NCT01456936 when participants received placebo in a triple-dummy design were analyzed as part of this study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="1121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Chalazion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Endocrine ophthalmopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Duodenal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Inguinal hernia strangulated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Hepatitis alcoholic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Haemorrhagic fever with renal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Periorbital haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Hepatosplenic T-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Morton’s neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Premature baby</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment disorder with depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Schizophrenia, paranoid type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Urinary bladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Drug detoxification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1121"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="165" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="160" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="116" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="143" subjects_at_risk="1121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="81" subjects_at_risk="1121"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="1192"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="1166"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="1116"/>
                <counts group_id="E4" subjects_affected="63" subjects_at_risk="1121"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

